Compare CAN & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAN | NBP |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.2M | 503.8M |
| IPO Year | 2019 | 2020 |
| Metric | CAN | NBP |
|---|---|---|
| Price | $0.76 | $3.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $3.56 | N/A |
| AVG Volume (30 Days) | ★ 18.8M | 963.9K |
| Earning Date | 11-18-2025 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $422,228,000.00 | N/A |
| Revenue This Year | $92.55 | N/A |
| Revenue Next Year | $41.93 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 83.87 | N/A |
| 52 Week Low | $0.53 | $0.60 |
| 52 Week High | $2.39 | $6.79 |
| Indicator | CAN | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 43.07 | N/A |
| Support Level | $0.77 | N/A |
| Resistance Level | $0.95 | N/A |
| Average True Range (ATR) | 0.06 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 30.75 | 0.00 |
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.